Skip to main content
. 2024 May 28;12(1):8–42. doi: 10.1002/ehf2.14857

Figure 2.

Figure 2

Cardiovascular (CV) and kidney outcomes with sodium–glucose co‐transporter‐2 inhibitor (SGLT2i) and finerenone in patients with chronic kidney disease (CKD). ACR, albumin‐to‐creatinine ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; ESKD, end‐stage kidney disease; HF, heart failure; HFH, heart failure hospitalization; HR, hazard ratio; MI, myocardial infarction; RR, rate ratio; T2DM, type 2 diabetes mellitus. *ESKD, sustained decrease in eGFR to <10 mL/min/1.73 m2, sustained decrease in eGFR of ≥40% from baseline or death from renal causes.